Court of Justice sides with Illumina over probe into GRAIL deal, FT reports

The European Court of Justice has agreed with Illumina’s claim that the European Commission had no grounds to scrutinize its $8B acquisition of cancer screening start-up GRAIL in 2021, superseding the commission’s earlier decision to block the deal, The Financial Times’ Javier Espinoza reports. “The commission is not authorized to encourage or accept referrals of proposed concentrations without a European dimension from national competition authorities where those authorities are not competent to examine those proposed concentrations under their own national law,” the court said.